arginyl-glutamine has been researched along with Lung-Neoplasms* in 1 studies
1 other study(ies) available for arginyl-glutamine and Lung-Neoplasms
Article | Year |
---|---|
A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer.
Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments.. A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued.. We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy. Topics: Aged; Antibodies, Monoclonal; Colonic Neoplasms; Dipeptides; ErbB Receptors; Humans; Lung Neoplasms; Male; Panitumumab; Prognosis; Skin Diseases; Valerates | 2014 |